Linalyl acetate prevents hypertension-related ischemic injury
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hsieh, Yu Shan | - |
dc.contributor.author | Kwon, Soonho | - |
dc.contributor.author | Lee, Hui Su | - |
dc.contributor.author | Seol, Geun Hee | - |
dc.date.accessioned | 2021-09-02T11:24:30Z | - |
dc.date.available | 2021-09-02T11:24:30Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-05-25 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/75492 | - |
dc.description.abstract | Ischemic stroke remains an important cause of disability and mortality. Hypertension is a critical risk factor for the development of ischemic stroke. Control of risk factors, including hypertension, is therefore important for the prevention of ischemic stroke. Linalyl acetate (LA) has been reported to have therapeutic effects in ischemic stroke by modulating intracellular Ca2+ concentration and having anti-oxidative properties. The preventive efficacy of LA has not yet been determined. This study therefore investigated the preventive efficacy of LA in rat aortas exposed to hypertension related-ischemic injury, and the mechanism of action of LA.Hypertension was induced in vivo following ischemic injury to the aorta induced by oxygen-glucose deprivation and reoxygenation in vitro. Effects of LA were assayed by western blotting, by determining concentrations of lactate dehydrogenase (LDH) and reactive oxygen species (ROS) and by vascular contractility assays. LA significantly reduced systolic blood pressure in vivo. In vitro, LA suppressed ischemic injury-induced expression of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunit p47(Phox), as well as ROS production, LDH release, and ROS-induced endothelial nitric oxide synthase suppression. These findings indicate that LA has anti-hypertensive properties that can prevent hypertension-related ischemic injury and can prevent NADPH oxidase-induced production of ROS. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.subject | NEURONAL CELL-DEATH | - |
dc.subject | HYPOXIA-ISCHEMIA | - |
dc.subject | ESSENTIAL OIL | - |
dc.subject | RISK-FACTOR | - |
dc.subject | IN-VITRO | - |
dc.subject | STROKE | - |
dc.subject | CHANNELS | - |
dc.subject | CALCIUM | - |
dc.subject | ASPIRIN | - |
dc.subject | THROMBOLYSIS | - |
dc.title | Linalyl acetate prevents hypertension-related ischemic injury | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seol, Geun Hee | - |
dc.identifier.doi | 10.1371/journal.pone.0198082 | - |
dc.identifier.scopusid | 2-s2.0-85047544550 | - |
dc.identifier.wosid | 000433153400038 | - |
dc.identifier.bibliographicCitation | PLOS ONE, v.13, no.5 | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.citation.title | PLOS ONE | - |
dc.citation.volume | 13 | - |
dc.citation.number | 5 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | NEURONAL CELL-DEATH | - |
dc.subject.keywordPlus | HYPOXIA-ISCHEMIA | - |
dc.subject.keywordPlus | ESSENTIAL OIL | - |
dc.subject.keywordPlus | RISK-FACTOR | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | STROKE | - |
dc.subject.keywordPlus | CHANNELS | - |
dc.subject.keywordPlus | CALCIUM | - |
dc.subject.keywordPlus | ASPIRIN | - |
dc.subject.keywordPlus | THROMBOLYSIS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.